Mizuho lowered the firm’s price target on Autolus Therapeutics (AUTL) to $10 from $12 and keeps an Outperform rating on the shares. The firm updated models in the small-cap biotech space following the Q4 reports.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AUTL:
- Autolus: Transition-Year Execution and Aucatzyl Expansion Underscore Buy-Rated Long-Term Upside
- Midday Fly By: Carnival cuts forecast on fuel cost, Novartis to buy Excellergy
- Autolus Highlights AUCATZYL Launch and Pipeline Advancements
- Morning Movers: AstraZeneca jumps following tozorakimab trial results
- Autolus Therapeutics reports Q4 EPS (34c), consensus (43c)